Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Abivax
Abivax
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Recruitment
Abivax strengthens its management team
Regulatory
ABIVAX’s ABX464 reduces HIV reservoir in blood in second phase clinical trial
ABX464 is the first drug candidate to show statistically significant (p<0.01) reduction of the HIV viral reservoir
Research & Development
Evotec and ABIVAX collaborate to develop novel antiviral agents
Evotec and ABIVAX have announced a strategic collaboration to discover and develop novel treatments for multiple viral infectious diseases
Regulatory
First ever evidence of treatment-induced reduction in HIV reservoirs
Preliminary clinical trial results support ABX464's potential to become a key functional cure element for HIV
Manufacturing
Abivax enters into a manufacturing agreement with PCAS for ABX464
Collaboration ensures drug candidate supply for upcoming clinical trials
Research & Development
Abivax makes three new personnel changes
Including the appointment of a new Chief Medical Officer
Pharmaceutical
Abivax makes two appointments to executive management team
Karl Birthistle joins as VP of Global Regulatory Affairs, while Daniel Kenny becomes VP of Business Development
Subscribe now